Answers are grounded in this paper and cite their sources.
Renal cell carcinoma (RCC) comprises a heterogeneous group of renal epithelial neoplasms with distinct morphologic, immunophenotypic, and molecular characteristics that increasingly influence diagnosis, prognosis, hereditary risk assessment, and therapeutic decision-making. Advances in molecular pathology have reshaped RCC classification, culminating in the 2022 World Health Organization (WHO) framework, which includes a dedicated category of molecularly defined renal carcinomas. Concurrently, fine-needle aspiration biopsy (FNAB) has assumed an important role in the evaluation of RCC, particularly at metastatic sites, requiring cytopathologists to establish accurate diagnoses from limited material while preserving tissue for ancillary testing. Although much of the evidence base for RCC molecular pathology derives from surgical specimens, cytologic samples can support immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS). This review provides a practical, entity-based overview of RCC molecular diagnostics from the perspective of the cytopathologist. For common RCCs and selected uncommon and molecularly defined renal tumors, we summarize characteristic cytomorphology, immunophenotype, molecular alterations, and the circumstances in which ancillary testing can refine classification or inform clinical management. Most conventional RCCs remain diagnosable through careful morphology and targeted IHC, whereas molecular testing is most informative in tumors with overlapping clear-cell, papillary, eosinophilic, or high-grade features and when a molecularly defined entity is suspected. Molecular findings may also raise concern for hereditary predisposition or identify clinically relevant alterations but should be interpreted within their morphologic and technical context. By combining cytomorphology with careful specimen stewardship, targeted IHC, and appropriately selected molecular testing, cytopathologists can use limited FNAB material to provide increasingly precise diagnoses that support appropriate clinical management.
No takes yet. Share an insight, caveat, or question.
Kleinjan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: